 |
|
New lead on malaria treatment
May 19, 2009Variation of natural compound cures malaria in mice
Approximately 350 million to 500 million cases of malaria are diagnosed each year mostly in sub-Saharan Africa. While medications to prevent and treat malaria do exist, the demand for new treatments is on the rise, in part, because malaria parasites have developed a resistance to existing medications. Now, researchers at the Johns Hopkins University School of Medicine have discovered one way to stop malaria parasite growth, and this new finding could guide the development of new malaria treatments.
"Our research on malaria is in line with Johns Hopkins' mission to address health problems on a global level," says Jun O. Liu, Ph.D., a professor of pharmacology and molecular sciences. "Our findings offer both a new potential molecular target for treating malaria and a compound that interacts at that target. These are important steps in discovering drugs that could help to treat malaria." The results of the research were published in the February 27 issue of Chemistry & Biology.
Liu's research team has for many years studied MetAP2 proteins, which are found in all organisms - from humans to single-celled bacteria - and essential for cell survival. They reasoned that if the malaria parasite has its own MetAP2, finding a chemical that disrupts MetAP2 function may lead to a new drug to stop parasite growth and malaria spread. So they searched a computer database of the sequence of the malaria parasite genome and found one protein very similar to human MetAP2, which they named PfMetAP2 for plasmodium falciparum, the parasite that causes malaria.
Recently other researchers reported that the natural antibiotic fumagillin can stop malaria parasites from growing, possibly by interfering with MetAP2. But the man-made version of fumagillin causes brain cells to die, so Liu's team made several compounds chemically related to fumagillin in hopes of finding one less toxic but still effective in interfering with PfMetAP2. They chose to further study one of these compounds, fumarranol, because it interacts with human MetAP2 and is less toxic to mice.
The team first tested whether fumarranol can stick to and interfere with PfMetAP2 by treating mouse cells containing PfMetAP2 with different amounts of fumarranol and fumagillin and comparing them to untreated cells. In treated cells, fumarranol stuck to PfMetAP2 and stopped it from working.
They next asked whether fumarranol could stop malaria parasites from growing in a culture dish. They treated both drug-resistant and multidrug-resistant strains of Plasmodium falciparum and found that fumarranol could stop the parasite from multiplying.
The team then gave mice infected with malaria fumarranol for four days after infection and measured the parasite load in the blood. They found that after four days, fumarranol worked as well as fumagillin to slow infection. After another 26 days they again measured parasites in the blood, found that some mice carried no observable level of parasites and considered these animals cured.
"The next step for establishing a new treatment for malaria would be to test whether fumarranol is the most optimal treatment or if new compounds that are similar to fumarranol might be even more specific to malaria parasites," Liu says.
Johns Hopkins Medical Institutions
Liu's research team has for many years studied MetAP2 proteins, which are found in all organisms - from humans to single-celled bacteria - and essential for cell survival. They reasoned that if the malaria parasite has its own MetAP2, finding a chemical that disrupts MetAP2 function may lead to a new drug to stop parasite growth and malaria spread. So they searched a computer database of the sequence of the malaria parasite genome and found one protein very similar to human MetAP2, which they named PfMetAP2 for plasmodium falciparum, the parasite that causes malaria.
Recently other researchers reported that the natural antibiotic fumagillin can stop malaria parasites from growing, possibly by interfering with MetAP2. But the man-made version of fumagillin causes brain cells to die, so Liu's team made several compounds chemically related to fumagillin in hopes of finding one less toxic but still effective in interfering with PfMetAP2. They chose to further study one of these compounds, fumarranol, because it interacts with human MetAP2 and is less toxic to mice.
The team first tested whether fumarranol can stick to and interfere with PfMetAP2 by treating mouse cells containing PfMetAP2 with different amounts of fumarranol and fumagillin and comparing them to untreated cells. In treated cells, fumarranol stuck to PfMetAP2 and stopped it from working.
They next asked whether fumarranol could stop malaria parasites from growing in a culture dish. They treated both drug-resistant and multidrug-resistant strains of Plasmodium falciparum and found that fumarranol could stop the parasite from multiplying.
The team then gave mice infected with malaria fumarranol for four days after infection and measured the parasite load in the blood. They found that after four days, fumarranol worked as well as fumagillin to slow infection. After another 26 days they again measured parasites in the blood, found that some mice carried no observable level of parasites and considered these animals cured.
"The next step for establishing a new treatment for malaria would be to test whether fumarranol is the most optimal treatment or if new compounds that are similar to fumarranol might be even more specific to malaria parasites," Liu says.
Johns Hopkins Medical Institutions
Malaria Current Events and Malaria News RSSPATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines
Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa.
Global challenges and opportunities in fighting HIV/AIDS and neglected diseases
Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs.
Media availability: The role of biomedical research in malaria eradication
Although malaria has been controlled in many local and regional populations, the permanent elimination of malaria parasites throughout the world remains an elusive goal, and the disease continues to claim nearly one million lives each year.
Ineffective monotherapies common in high-burden malarious countries
ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk.
New tool promises more accurate antimalarial drug dosing
Scientists at LSTM have developed a tool to support the development of appropriate age-based dosing regimens for malaria drugs.
Cell phones become handheld tools for global development
Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment.
Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.
UM School of Medicine researchers find extreme genetic variability in malaria parasite
Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world.
Outfoxing pox: Developing a new class of vaccine candidates
In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox.
Ironing out the genetic cause of hemoglobin problems
A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.
More Malaria Current Events and Malaria News Articles
 |
The Making of a Tropical Disease: A Short History of Malaria (Johns Hopkins Biographies of Disease) by Randall M. Packard (Author) Malaria sickens hundreds of millions of people -- and kills one to three million -- each year. Despite massive efforts to eradicate the disease, it remains a major public health problem in poorer tropical regions. But malaria has not always been concentrated in tropical areas. How did other regions control malaria and why does the disease still flourish in some parts of the globe? From Russia to Bengal to Palm Beach, Randall Packard's far-ranging narrative traces the natural and social forces that help malaria spread and make it deadly. He finds that war, land development, crumbling health systems, and globalization -- coupled with climate change and changes in the distribution and flow of water -- create conditions in which malaria's carrier mosquitoes thrive. The combination of... |
 |
The Malaria Capers : More Tales of Parasites and People, Research and Reality by Robert S. Desowitz (Author) "Reads like a murder mystery. . . . [Desowitz] writes with uncommon lucidity and verse, leaving the reader with a vivid understanding of malaria and other tropical diseases, and the ways in which culture, climate and politics have affected their spread and containment."—New York Times Why, Robert S. Desowitz asks, has biotechnical research on malaria produced so little when it had promised so much? An expert in tropical diseases, Desowtiz searches for answers in this provocative book. . |
![GIANTmicrobes: Malaria (Plasmodium Falciparum) [Toy]](http://ecx.images-amazon.com/images/I/21%2BeHMzjARL._SL160_.jpg) |
GIANTmicrobes: Malaria (Plasmodium Falciparum) [Toy] by Giant Microbes GIANTmicrobes are fun and educationala great way to learn about various health topics and the microscopic critters that are found in and around us. Each microbe character is 5-7 in size--over a million times their actual size! Perfect for teachers, parents and budding scientiststhey also make humorous gifts. Each microbe comes with an information tag including scientific name, an image of the actual microbe, and a mini history and science lesson. Not suitable for children under 3 years. Our products are made by top manufacturers who care about toy safety, quality and value. Your order will ship factory fresh directly from our warehouse to your door. We carefully inspect and beautifully package every order before shipment to ensure that you receive high quality products that are... |
 |
Humanity's Burden: A Global History of Malaria (Studies in Environment and History) by James L.A. Webb Jr. (Author) Humanity's Burden provides a panoramic overview of the history of malaria. It traces the long arc of malaria out of tropical Africa into Eurasia, its transfer to the Americas during the early years of the Columbian exchange, and its retraction from the middle latitudes into the tropics since the late nineteenth century. Adopting a broadly comparative approach to historical patterns and processes, it synthesizes research findings from the natural and social sciences and weaves these understandings into a narrative that reaches from the earliest evidence of malaria infections in tropical Africa up to the present. Written in a style that is easily accessible to non-specialists, it considers the significance of genetic mutations, diet, lifestyle, migration, warfare, palliative and curative... |
 |
Compiled 1981-1984 by Malaria! |
 |
First Comes Love, Then Comes Malaria: How a Peace Corps Poster Boy Won My Heart and a Third World Adventure Changed My Life by Eve Brown-Waite (Author) In this laugh-out-loud funny memoir, a pampered city girl falls head over little black heels in love with a Peace Corps poster boy and follows him —literally–to the ends of the earth. Eve Brown always thought she would join the Peace Corps someday, although she secretly worried about life without sushi, frothy coffee drinks and air conditioning. But with college diploma in hand, it was time to put up or shut up. So with some ambivalence she arrives at the Peace Corps office–sporting her best safari chic attire –to casually look into the steps one might take if one were to become a global humanitarian, a la Angelina Jolie. But when Eve meets John, her dashing young Peace Corps recruiter, all her ambivalence flies out the window. She absolutely must join the Peace Corps -... |
 |
Malaria: Fever Wars Starring: Artist Not Provided |
 |
Parasites! - The Malaria Parasite by Sheila Wyborny (Author) Malaria is a serious disease caused by a tiny mosquito-borne parasite called Plasmodium. It once affected entire empires, but thanks to the work of health organizations, malaria is now mostly confined to warm, moist climates. Scientists are still at work today, however, developing methods of curing the disease and destroying its carriers. |
 |
Compiled 1981-84 Malaria! (Primary Contributor) |
 |
Molecular Approaches to Malaria by Irwin W. Sherman (Editor) "Molecular Approaches to Malaria" provides an overview of the rapid and significant developments that have occurred in malaria research, including the 2002 genome sequencing of Plasmodium falciparum and its mosquito vector, Anopheles gambiae. This work: provides a concise source of up-to-date research findings; appeals to a diverse audience, including malaria researchers, teachers, investigators, and public health professionals; offers contributions by recognized malaria researchers with practical experience; and, presents comprehensive coverage of topics including a clearly written introduction to Plasmodium molecular biology. |
| © 2009 BrightSurf.com |